Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
The Journal of Sexual Medicine
|
November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study
Gil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
Arthritis Research & Therapy
|
January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
Bernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Rheumatology (Oxford, England)
|
June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
American Journal of Clinical Dermatology
|
March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Journal of the American Academy of Dermatology
|
November 13, 2019
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Patient Preference and Adherence
|
March 27, 2020
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 29, 2019
Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab
Andrew Blauvelt, Nianwen Shi, Baojin Zhu, et al.
Journal of Managed Care & Specialty Pharmacy
|
February 24, 2017
Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials
William Malatestinic, Beth Nordstrom, Jashin J Wu, et al.
Journal of the American Academy of Dermatology
|
October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the National Cancer Institute
|
October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
Susan Halabi, Chen-Yen Lin, Eric J Small, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
The Journal of Sexual Medicine
|
November 13, 2018
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study
Gil Yosipovitch, Peter Foley, Caitriona Ryan, et al.
Arthritis Research & Therapy
|
January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
Bernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Rheumatology (Oxford, England)
|
June 27, 2018
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, et al.
American Journal of Clinical Dermatology
|
March 1, 2023
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Ohsang Kwon, Maryanne M Senna, Rodney Sinclair, et al.
Journal of the American Academy of Dermatology
|
November 13, 2019
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Patient Preference and Adherence
|
March 27, 2020
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Journal of Managed Care & Specialty Pharmacy
|
November 29, 2019
Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab
Andrew Blauvelt, Nianwen Shi, Baojin Zhu, et al.
Journal of Managed Care & Specialty Pharmacy
|
February 24, 2017
Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials
William Malatestinic, Beth Nordstrom, Jashin J Wu, et al.
Journal of the American Academy of Dermatology
|
October 4, 2016
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, et al.
Journal of the National Cancer Institute
|
October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
Susan Halabi, Chen-Yen Lin, Eric J Small, et al.
Page
of 5